Exscientia Stock: Drug Discovery Platform Attracting Partners And Cash (NASDAQ:EXAI)
Morsa Images As Generative AI impacts drug research, this thesis aims to uncover the opportunities for Exscientia plc (NASDAQ:EXAI) and show it is a buy based on the strength of its technology platform. Noteworthily, I was again bullish when covering the stock in April 2022 priced at $12. It did rise to $15.21, but, subsequently,…